Jun 30, 2021

Penumbra Q2 2021 Earnings Report

Penumbra's revenue increased significantly, driven by strong growth in both vascular and neuro products, resulting in a return to operating income.

Key Takeaways

Penumbra, Inc. reported a strong second quarter with a 75.3% increase in revenue compared to the previous year, reaching $184.3 million. The company achieved an operating income of $10.3 million, a significant improvement from the operating loss in the same quarter of the previous year. The company is increasing its guidance for 2021 total revenue to be in the range of $720 million to $730 million.

Total revenue increased by 75.3% to $184.3 million compared to Q2 2020.

Vascular product revenue grew by 117.6% to $100.7 million.

Neuro product revenue increased by 42.0% to $83.6 million.

Operating income was $10.3 million, a significant improvement from the $17.6 million operating loss in Q2 2020.

Total Revenue
$184M
Previous year: $105M
+75.3%
EPS
$0.21
Previous year: -$0.3
-170.0%
Gross Margin
64.4%
Previous year: 61.8%
+4.2%
Gross Profit
$119M
Previous year: $64.9M
+82.8%
Cash and Equivalents
$82.3M
Previous year: $134M
-38.8%
Free Cash Flow
-$6.61M
Previous year: -$28.4M
-76.7%
Total Assets
$910M
Previous year: $780M
+16.7%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

The Company is increasing its guidance for 2021 total revenue to be in the range of $720 million to $730 million, which represents 28% to 30% growth over 2020 revenue of $560.4 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income